Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Prostate-specific Antigen
100%
Biochemical Recurrence
100%
Primary Radiotherapy
100%
Phoenix Criteria
100%
Advanced Imaging
50%
Low Risk
33%
High Risk
33%
Phoenix
33%
PET-computed Tomography
33%
Prostate-specific Antigen Kinetics
33%
Clinical Practice Guidelines
16%
Improved Outcomes
16%
Diagnostic Tool
16%
Clinical High Risk
16%
Radiotherapy
16%
Recurrent Prostate Cancer
16%
Patient Outcomes
16%
Salvage Treatment
16%
Prognostic Information
16%
Clinical Features
16%
Overtreatment
16%
Prostate-specific Antigen Level
16%
Non-cancer
16%
Cancer Recurrence
16%
Clinical Utility
16%
Doubling Time
16%
Prognostic Tool
16%
Potential Alternatives
16%
Multi-parameter
16%
Risk Model
16%
Current Diagnostics
16%
Surveillance Strategy
16%
Precision Oncology
16%
Disease Biology
16%
Outcome Reporting
16%
Risk-adapted Treatment
16%
Computed Tomography Findings
16%
Kinetic Characteristics
16%
Early Risk
16%
Prostate-specific Antigen Bounce
16%
Early Salvage
16%
Medicine and Dentistry
Biochemical Recurrence
100%
Prostate Specific Antigen
100%
Radiation Therapy
100%
Computer Assisted Tomography
25%
Prostate Specific Membrane Antigen
25%
Polyethylene Terephthalate
25%
Clinical Guideline
12%
Imaging Technique
12%
Prostate Cancer
12%
Clinical Feature
12%
Cancer Recurrence
12%
Diseases
12%
Precision Oncology
12%
Pharmacology, Toxicology and Pharmaceutical Science
Biochemical Recurrence
100%
Prostate Specific Antigen
100%
Prostate Specific Membrane Antigen
25%
Polyethylene Terephthalate
25%
Prostate Cancer
12%
Clinical Feature
12%
Cancer Recurrence
12%
Diseases
12%
Immunology and Microbiology
Prostate Specific Antigen
100%
Prostate Specific Membrane Antigen
25%
Computer Assisted Tomography
25%